A revolutionary new blood test has the potential to transform the diagnosis and treatment of Alzheimer’s disease. Not only does this innovative test confirm the presence of the disease, but it also provides critical information regarding the stage of its progression, fundamentally changing how physicians manage Alzheimer’s care.
This groundbreaking test was developed by a team of experts at Washington University School of Medicine in St. Louis and Lund University in Sweden. Their studies reveal that a specific blood protein, known as MTBR-tau243, can effectively monitor the accumulation of dangerous tau proteins in the brain. These tau tangles are among the hallmark characteristics of Alzheimer’s and correlate directly with the severity of the symptoms.
One of the most significant advantages of this new technique is its non-invasive nature, making it considerably more convenient than traditional brain scans. Unlike expensive procedures that are often difficult to access, this blood test can be administered easily, allowing for a broader reach in patient diagnosis and monitoring.
Currently, physicians use various blood tests to aid in the detection of Alzheimer’s. Some of these tests, based on earlier discoveries at Washington University, identify early warning signs but do not provide insight into the extent of disease progression. This gap in knowledge is crucial, as Alzheimer’s treatments are most effective during the early stages when damage is minimal.
Understanding whether an individual is in the early or late phase of Alzheimer’s can significantly aid doctors in determining the most effective treatment pathways. Furthermore, it can clarify whether an individual’s cognitive issues stem from Alzheimer’s or alternative conditions. Dr. Randall J. Bateman, co-senior author of the study, emphasized, “This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia.”
Alzheimer’s typically begins with a buildup of amyloid proteins in the brain, with tau tangles developing later, marking the onset of symptoms. Traditionally, PET scans have been the go-to method for tracking amyloid and tau deposits; however, these scans are expensive and time-consuming. Thus, scientists have been pursuing blood-based alternatives.
To validate the effectiveness of the new blood test, researchers analyzed data from two distinct groups. The first group comprised 108 volunteers from a research center at Washington University, while the second group included 55 participants from the Swedish study known as BioFINDER-2. The researchers further corroborated their findings with data from an additional 739 participants in the BioFINDER-2 group, representing various stages of Alzheimer’s from asymptomatic individuals with amyloid presence to those with full-blown dementia.
The results were quite promising. The levels of MTBR-tau243 in the blood matched the amount of tau tangles in the brain with an impressive accuracy of 92%. In healthy individuals and those in the earliest stages of Alzheimer’s, the levels were normal. However, in symptomatic individuals, the protein levels were significantly elevated, providing clear differentiation between early and late-stage Alzheimer’s.
This revolutionary test is based on technology licensed by Washington University to C2N Diagnostics, which has previously developed similar blood tests for amyloid plaques. The earlier tests were designed for another tau protein called p-tau217. According to Oskar Hansson, a professor of neurology at Lund University, “When both of these biomarkers are positive, the likelihood that Alzheimer’s is the underlying cause of a person’s cognitive symptoms increases significantly.”
Currently, there are two FDA-approved drugs targeting amyloid in the brain to slow Alzheimer’s progression, with more treatments under investigation. As new therapies emerge, reliable blood tests will be crucial in matching the right treatment to each disease stage. Kanta Horie, a research associate professor of neurology at WashU Medicine, stated, “We’re about to enter the era of personalized medicine for Alzheimer’s disease.”
With the development of this new blood test, doctors will soon have a clinically available method for staging Alzheimer’s, along with treatments tailored for different disease stages. This advancement promises to optimize treatment plans to meet the specific needs of each patient. The full study can be found in the journal Nature Medicine.
Interested in more engaging articles and exclusive content? Subscribe to our newsletter for the latest updates on developments in Alzheimer’s care and other health topics.
